Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Pharmaceutical company Eli Lilly and Company detracted from performance as pricing pressure and competitive concerns weighed on sentiment. Shares declined following...
— Neal Kaufman
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly & Co.
Eli Lilly is a premier multinational pharmaceutical company engaged in the research, development, and commercialization of therapeutics, currently dominating the global market for diabetes and obesity treatments. The manager is...
The company remains a premier growth compounder in the highly underserved global diabetes and obesity therapeutic markets. While the market...
Eli Lilly is the eleventh largest holding. Global branded pharmaceutical...
More institutional theses from Baron Health Care Fund
Thermo Fisher Scientific Inc. ($TMO) is the world's premier provider of life sciences tools, laboratory supplies, analytical instruments, and clinical trial services, representing 5.9% of fund assets. The investment manager...
Xenon Pharmaceuticals Inc. ($XENE) is a clinical-stage biopharmaceutical developer focused on novel ion channel therapies for neurological disorders. The manager adopted...
Mettler-Toledo International Inc. ($MTD) manufactures precision laboratory balances, analytical instruments, and industrial inspection systems essential for research and quality assurance, comprising 7.5% of fund assets. The manager holds...